Targeting SIRT1 with inhibitors such as EX-527 or MHY2256 has shown promise in sensitizing endometrial cancer cells to chemotherapy and overcoming chemoresistance [114,153]. This evidence concerns the gene SIRT1 and endometrial cancer.